Compare ONCO & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONCO | GXAI |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 8.8M |
| IPO Year | 2022 | 2023 |
| Metric | ONCO | GXAI |
|---|---|---|
| Price | $1.58 | $1.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 58.8K | ★ 152.8K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,223,751.00 | $694,278.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23205.74 |
| 52 Week Low | $1.37 | $1.00 |
| 52 Week High | $179.35 | $3.36 |
| Indicator | ONCO | GXAI |
|---|---|---|
| Relative Strength Index (RSI) | 33.81 | 39.11 |
| Support Level | $1.37 | $1.02 |
| Resistance Level | $1.66 | $1.20 |
| Average True Range (ATR) | 0.20 | 0.08 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 14.48 | 13.04 |
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.